MedTrace Logo

A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer

NCT06232863 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-02-02

No results posted yet for this study

Summary

This study will assess the safety and tolerability and pharmacokinetics of BH009 in patients with advanced head and neck squamous (non-nasopharyngeal) and ovarian cancer.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

BH009

Every 28 days constitutes a treatment cycle, and administration on day 1, day 8, day 15 of each cycle

Sponsors & Collaborators

  • Zhuhai Beihai Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Jing Wang, PI · Hunan Cancer Hospital

  • Yaqian Han, PI · Hunan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-18
Primary Completion
2024-03-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06232863 on ClinicalTrials.gov